Abstract The first endothelin (ET)-1 receptor antagonist was approved for clinical use over
20 years ago, but to date this class of compounds has been limited to treating pulmonary …

Gastrodia elata Blume (GEB), commonly called Tianma in Chinese, is a valuable and
extensively used herbal Traditional Chinese Medicine with a wide range of clinical …

Abstract Aprocitentan (ACT-132577) is an orally active, dual endothelin-1 (ET-1) receptor
antagonist that prevents the binding of ET-1 to both ETA/ETB receptors. It is an active …

The effect of moderate hepatic impairment on the pharmacokinetics (PK), safety, and
tolerability of the dual endothelin receptor antagonist aprocitentan was clinically investigated …

Hypertension is associated with the flow of blood under high pressures, yet the
complications of hypertension, such as myocardial infarction or stroke are paradoxically …

The endothelin (ET) system has emerged as a novel target for hypertension treatment where
a medical need persists despite availability of several pharmacological classes, including …

Spontaneously hypertensive rats (SHRs) exhibit endothelial dysfunction and insulin
resistance. Reciprocal relationships between endothelial dysfunction and insulin resistance …

Diabetes and arterial hypertension continue to be the main causes of chronic renal failure in
2010, with a rising prevalence in part due to the worldwide obesity epidemic. Proteinuria is a …

Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary
vasculature involving endothelial and vascular smooth muscle cell (VSMC) proliferation …

Endothelium is now recognized as a massive, regionally specific, multifunctional organ.
Given its strategic anatomic location between the circulating blood components and the …